Physician profile
Zongda Chen
NPI 1447516885
$438.05
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.82 · 2020: $224 · 2021: $179.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $88.16 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.76 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $37.03 | 2020-2021 | |
| Lilly USA, LLC | $32.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $27.32 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $23.96 | 2021 | |
| Redhill Biopharma INC. | $22.74 | 2020 | |
| Amarin Pharma, INC. | $22.56 | 2021 | |
| Abbvie INC. | $22.49 | 2021 | |
| Eyevance Pharmaceuticals LLC | $19.43 | 2021 | |
| Glaxosmithkline, LLC. | $18.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.52 | 2021 | |
| Allergan, INC. | $14.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.77 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.65 | 2021 | |
| Horizon Therapeutics Plc | $11.24 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zongda Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.